News und Analysen
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm highlighted upcoming milestones for selinexor, including an ASCO late-breaking
Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet
Key Points
- Interested in Alphabet Inc.? Here are five stocks we like better.
- At Google I/O 2026, Alphabet unveiled a suite of new AI models and features, including Gemini 3.5 Flash, Omni, and
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm said it will present fuller Phase 3 SENTRY data for selinexor in newly diagnosed
KLA Flags Stronger Chip Equipment Demand, Rare 2027 Visibility at JPMorgan Conference
Key Points
- Interested in KLA Corporation? Here are five stocks we like better.
- KLA said semiconductor equipment demand is strengthening across leading-edge logic, memory and advanced
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit einem Gesamtvolumen von rund EUR 1 Milliarde in Tranchen
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit einem Gesamtvolumen von rund EUR 1 Milliarde in Tranchen
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Key Points
- Interested in Opus Genetics, Inc.? Here are five stocks we like better.
- Opus Genetics highlighted a broad inherited retinal disease gene therapy pipeline, with two programs already
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis has a packed 2026-style catalyst calendar with two PDUFA dates for wholly owned drugs —
Google Cloud Security schult auf der Google Next 2026 mit Instruqt über 150 Fachkräfte in agentischer KI
Die praxisorientierte Plattform von Instruqt stellt jedem Teilnehmer eine eigene Vertex-AI-Umgebung bereit und zeigt damit ein neues Modell, um die Lücke bei der KI-Nutzung auch auf Konferenzniveau
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Key Points
- Interested in Inovio Pharmaceuticals, Inc.? Here are five stocks we like better.
- Shareholders approved all proposals at Inovio’s 2026 annual meeting, including the election of eight
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte plans to start a Phase 3 trial of mutant CALR antibody 989 in essential thrombocythemia around
GlobalFoundries Eyes AI, Data Center Growth as It Targets 40% Margins
Key Points
- Interested in GlobalFoundries Inc.? Here are five stocks we like better.
- GlobalFoundries said it is positioning itself for growth in AI, data centers, silicon photonics, and custom
Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
Key Points
- Interested in Deckers Outdoor Corporation? Here are five stocks we like better.
- Deckers posted record revenue and EPS, supported primarily by HOKA and UGG growth.
- International sales
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Exelixis is leaning on CABO growth in renal cell carcinoma and neuroendocrine tumors, with management emphasizing
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYKORZO’s launch is outperforming expectations, with Cytokinetics saying early prescriptions
EQS-News: Fresenius-Hauptversammlung 2026: Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu
EQS-News: Fresenius-Hauptversammlung 2026: Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu
Booz Allen Hamilton Q4 Earnings Call Highlights
Key Points
- Interested in Booz Allen Hamilton Holding Corporation? Here are five stocks we like better.
- Revenue fell in fiscal 2026, but profitability beat expectations. Booz Allen reported
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen's diranersen missed its primary endpoint in the Phase 2 CELIA trial, sending BIIB shares down more than 10% on
EQS-Adhoc: Neubesetzung des Vorstandsvorsitzes der Carl Zeiss Meditec AG
EQS-Adhoc: Neubesetzung des Vorstandsvorsitzes der Carl Zeiss Meditec AG
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
Key Points
- Interested in CorMedix Inc? Here are five stocks we like better.
- CorMedix sees a potential expansion of REZZAYO into fungal infection prophylaxis, with preliminary data showing
EQS-News: Eckert & Ziegler erhält erneut „Best Managed Companies Award“
EQS-News: Eckert & Ziegler erhält erneut „Best Managed Companies Award“
EQS-News: Hauptversammlung 2026: Fresenius blickt auf sehr gutes Geschäftsjahr 2025 zurück und schlägt 5% mehr Dividende vor
EQS-News: Hauptversammlung 2026: Fresenius blickt auf sehr gutes Geschäftsjahr 2025 zurück und schlägt 5% mehr Dividende vor
Webull Q1 Earnings Call Highlights
Key Points
- Interested in Webull Corporation? Here are five stocks we like better.
- Webull posted strong Q1 growth, with revenue up 36% year over year to $159.9 million as trading activity
Amazon.com Shareholders Back Board as Jassy Touts AI, AWS Growth at Annual Meeting
Key Points
- Interested in Amazon.com, Inc.? Here are five stocks we like better.
- Amazon shareholders approved the board’s director nominees, ratified Ernst & Young as auditor for fiscal 2026 and
AEVIS VICTORIA SA – Ordentliche Generalversammlung: alle Anträge genehmigt
AEVIS VICTORIA SA – Ordentliche Generalversammlung: alle Anträge genehmigt
EQS-Adhoc: MeVis Medical Solutions AG: Halbjahresergebnis und Prognoseanpassung für das Geschäftsjahr 2025/2026
EQS-Adhoc: MeVis Medical Solutions AG: Halbjahresergebnis und Prognoseanpassung für das Geschäftsjahr 2025/2026